Brief: EMA Gets Application For Marketing Authorisation For Regkirona For Treating COVID-19
04/10/2021 13:00
Oct 4 (Reuters) - European Medicines Agency:
* EMA RECEIVES APPLICATION FOR MARKETING AUTHORISATION FOR
REGKIRONA (REGDANVIMAB) FOR TREATING PATIENTS WITH COVID-19
* EMA SAYS WILL ASSESS THE BENEFITS AND RISKS OF REGKIRONA
UNDER A
REDUCED TIMELINE AND COULD ISSUE AN OPINION WITHIN TWO MONTHS
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares